William Blair Investment Management LLC increased its holdings in GeneDx Holdings Corp. (NASDAQ:WGS – Free Report) by 11.4% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,560,247 shares of the company’s stock after purchasing an additional 159,594 shares during the period. William Blair Investment Management LLC owned approximately 5.23% of GeneDx worth $112,806,000 at the end of the most recent quarter.
Several other hedge funds also recently modified their holdings of the company. Russell Investments Group Ltd. raised its holdings in shares of GeneDx by 271.7% in the third quarter. Russell Investments Group Ltd. now owns 44,167 shares of the company’s stock valued at $3,193,000 after buying an additional 32,286 shares during the last quarter. Calamos Advisors LLC bought a new stake in shares of GeneDx during the third quarter worth $225,000. Moody Aldrich Partners LLC raised its position in GeneDx by 131.9% in the 3rd quarter. Moody Aldrich Partners LLC now owns 36,064 shares of the company’s stock valued at $2,607,000 after buying an additional 20,511 shares during the last quarter. Sterling Capital Management LLC increased its stake in GeneDx by 851.4% in the 3rd quarter. Sterling Capital Management LLC now owns 666 shares of the company’s stock valued at $48,000 after buying an additional 596 shares during the last quarter. Finally, Assenagon Asset Management S.A. raised its stake in shares of GeneDx by 108.4% during the 3rd quarter. Assenagon Asset Management S.A. now owns 632,413 shares of the company’s stock worth $45,723,000 after purchasing an additional 328,980 shares in the last quarter. Institutional investors and hedge funds own 61.72% of the company’s stock.
GeneDx Price Performance
Shares of WGS opened at $52.37 on Monday. The company has a debt-to-equity ratio of 0.60, a current ratio of 4.16 and a quick ratio of 3.85. GeneDx Holdings Corp. has a one year low of $32.21 and a one year high of $170.87. The company has a market cap of $1.56 billion, a P/E ratio of -13.85 and a beta of 2.00. The firm has a 50 day simple moving average of $73.83 and a two-hundred day simple moving average of $70.20.
GeneDx (NASDAQ:WGS – Get Free Report) last released its quarterly earnings data on Monday, November 9th. The company reported $0.28 earnings per share for the quarter, beating the consensus estimate of $0.07 by $0.21. GeneDx had a positive return on equity of 1.98% and a negative net margin of 24.10%. The business had revenue of $123.10 million for the quarter, compared to analyst estimates of $122.93 million. During the same period last year, the firm posted ($0.27) earnings per share. Research analysts forecast that GeneDx Holdings Corp. will post -0.41 EPS for the current fiscal year.
Insiders Place Their Bets
In other news, CEO Katherine Stueland sold 10,501 shares of GeneDx stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $97.61, for a total transaction of $1,025,002.61. Following the transaction, the chief executive officer owned 115,476 shares in the company, valued at approximately $11,271,612.36. The trade was a 8.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Kevin Feeley sold 3,728 shares of GeneDx stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $97.61, for a total value of $363,890.08. Following the transaction, the chief financial officer directly owned 44,945 shares in the company, valued at $4,387,081.45. The trade was a 7.66% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 19,206 shares of company stock worth $1,808,056 in the last 90 days. 25.17% of the stock is currently owned by corporate insiders.
Analyst Upgrades and Downgrades
WGS has been the subject of several research analyst reports. Weiss Ratings reiterated a “sell (d)” rating on shares of GeneDx in a research note on Monday, November 2nd. Wall Street Zen raised GeneDx from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. BTIG Research reaffirmed a “buy” rating and issued a $85.00 target price (down from $90.00) on shares of GeneDx in a research report on Tuesday, November 10th. Guggenheim increased their target price on GeneDx from $74.00 to $83.00 and gave the stock a “buy” rating in a research note on Thursday, October 1st. Finally, Canaccord Genuity Group lifted their price target on GeneDx from $75.00 to $90.00 and gave the stock a “buy” rating in a report on Tuesday, August 4th. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $90.14.
Get Our Latest Stock Report on GeneDx
GeneDx Profile
GeneDx is a genomic testing company focused on helping clinicians diagnose rare and inherited conditions. Its services include whole exome and whole genome sequencing, along with other genetic tests and clinical interpretation of results. The company’s testing is used by healthcare providers to support diagnosis and care decisions, particularly for patients with suspected rare genetic disorders. GeneDx also offers testing related to hereditary cancer risk. Founded in 2000 by researchers with experience at the National Institutes of Health, GeneDx has developed its business around applying genomic information in clinical care.
Featured Stories
- Five stocks we like better than GeneDx
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
Want to see what other hedge funds are holding WGS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GeneDx Holdings Corp. (NASDAQ:WGS – Free Report).
Receive News & Ratings for GeneDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeneDx and related companies with MarketBeat.com's FREE daily email newsletter.
